Infliximab-induced skin manifestations in patients with inflammatory bowel disease

References

• Dignass A, Van Assche G, Lindsay JO, et al. The second European evidence-based consensus on the diagnosis and management of Crohn's disease: current management. J Crohns Colitis. 2010;4:28–62.
   PubMed Web of Science ®Google Scholar
• Dignass A, Lindsay JO, Sturm A, et al. Second European evidence-based consensus on the diagnosis and management of ulcerative colitis. Part 2: current management. J Crohns Colitis. 2012;6:991–1030.
   PubMed Web of Science ®Google Scholar
• Van Assche G, Lewis JD, Lichtenstein GR, et al. The London position statement of the World Congress of Gastroenterology on Biological Therapy for IBD with the EuropeanCrohn's and Colitis Organisation: safety. Am J Gastroenterol. 2011;106:1594–1602.
   PubMed Web of Science ®Google Scholar
• Mocci G, Marzo M, Papa A, et al. Dermatological adverse reactions during anti-TNF treatments: focus on inflammatory bowel disease. J Crohns Colitis. 2013;7:769–779.
   PubMed Web of Science ®Google Scholar
• Mälkönen T, Wikström A, Heiskanen K, et al. Skin reactions during anti-TNFα therapy for pediatric inflammatory bowel disease: a 2-year prospective study. Inflamm Bowel Dis. 2014;20:1309–1315.
   PubMed Web of Science ®Google Scholar
• Hiremath G, Duffy L, Leibowitz I. Infliximab-induced psoriasis in children with inflammatory bowel disease. J Pediatr Gastroenterol Nutr. 2011;52:230–232.
   PubMed Web of Science ®Google Scholar
• Sherlock ME, Walters T, Tabbers MM, et al. Infliximab-induced psoriasis and psoriasiform skin lesions in pediatric Crohn disease and a potential association with IL-23 receptor polymorphisms. J Pediatr Gastroenterol Nutr. 2013;56:512–518.
   PubMed Web of Science ®Google Scholar
• Flendrie M, Vissers WHPM, Creemers MCW, et al. Dermatological conditions during TNF-alpha-blocking therapy in patients with rheumatoid arthritis: a prospective study. Arthritis Res Ther. 2005;7:R666–R676.
   PubMed Web of Science ®Google Scholar
• Lee HH, Song IH, Friedrich M, et al. Cutaneous side-effects in patients with rheumatic diseases during application of tumour necrosisfactor-alpha antagonists. Br J Dermatol. 2007;156:486–491.
   PubMed Web of Science ®Google Scholar
• Machado NP, Torresdos Reis Neto E, Soares MRMP, et al. The skin tissue is adversely affected by TNF-alpha blockers in patients with chronic inflammatory arthritis: a 5-year prospective analysis. Clinics. 2013;68:1189–1196.
   PubMed Web of Science ®Google Scholar
• Tillack C, Ehmann LM, Friedrich M, et al. Anti-TNF antibody-induced psoriasiform skin lesions in patients with inflammatory bowel disease are characterised by interferon-γ-expressing Th1 cells and IL-17A/IL-22-expressing Th17 cells and respond to anti-IL-12/IL-23 antibody treatment. Gut. 2014;63:567–577.
   PubMed Web of Science ®Google Scholar
• Denadai R, Teixeira FV, Steinwurz F, et al. Induction or exacerbation of psoriatic lesions during anti-TNF-α therapy for inflammatory bowel disease: a systematic literature review based on 222 cases. J Crohns Colitis. 2013;7:517–524.
   PubMed Web of Science ®Google Scholar
• Baumgart DC, Grittner U, Steingräber A, et al. Frequency, phenotype, outcome and therapeutic impact of skin reactions following initiation of Adalimumab therapy: experience from a consecutive cohort of inflammatory bowel disease patients. Inflamm Bowel Dis. 2011;17:2512–2520.
   PubMed Web of Science ®Google Scholar
• Włodarczyk M, Sobolewska A, Wójcik B, et al. Correlations between skin lesions induced by anti-tumor necrosis factor-α and selected cytokines in Crohn’s disease patients. World J Gastroenterol. 2014;20:7019–7026.
   PubMed Web of Science ®Google Scholar
• Huang VWM, Dhami N, Fedorak D, et al. A study investigating the association of dermatological and infusion reactions to infliximab and infliximab trough levels. Can J Gastroenterol. 2015;29:35–40.
   Web of Science ®Google Scholar
• Fidder H, Schnitzler F, Ferrante M, et al. Long-term safety of infliximab for the treatment of inflammatory bowel disease: a single-centre cohort study. Gut. 2009;58:501–508.
   PubMed Web of Science ®Google Scholar
• Cullen G, Kroshinsky D, Cheifetz AS, et al. Psoriasis associated with anti-tumournecrosis factor therapy in inflammatory bowel disease: a new series and a review of 120 cases from the literature. Aliment Pharmacol Ther. 2011;34:1318–1327.
   PubMed Web of Science ®Google Scholar
• Guerra I, Algaba A, Pérez-Calle JL, et al. Induction of psoriasis with anti-TNF agents in patients with inflammatory bowel disease: a report of 21 cases. J Crohns Colitis. 2012;6:518–523.
   PubMed Web of Science ®Google Scholar
• Cleynen I, Vermeire S. Paradoxical inflammation induced by anti-TNF agents in patients with IBD. Nat Rev Gastroenterol Hepatol. 2012;9:496–503.
   PubMed Web of Science ®Google Scholar
• Hernández MV, Sanmartí R, Cañete JD, et al. Cutaneous adverse events during treatment of chronic inflammatory rheumatoid conditions with tumor necrosis factor antagonists: study using the Spanish Registry of adverse events of biological therapies in rheumatoid diseases. Arthritis Care Res. 2013;65:2024–2031.
   Web of Science ®Google Scholar
• Collamer AN, Battafano DF. Psoriatic skin lesions induced by tumor necrosis factor antagonist therapy: clinical features and possible immunopathogenesis. Semin Arthritis Rheum. 2010;40:233–240.
   PubMed Web of Science ®Google Scholar
• Ma HL, Napierata L, Stedman N, et al. Tumor necrosis factoralpha blockade exacerbates murine psoriasis-like disease by enhancing Th17 function and decreasing expansion of Treg cells. Arthritis Rheum. 2010;62:430–440.
   PubMed Web of Science ®Google Scholar
• Brand S. Crohn's disease: Th1, Th17 or both? The change of a paradigm: new immunological and genetic insights implicate Th17 cells in the pathogenesis of Crohn's disease. Gut. 2009;58:1152–1167.
   PubMed Web of Science ®Google Scholar
• Koga C, Kabashima K, Shiraishi N, et al. Possible pathogenic role of Th17 cells for atopic dermatitis. J Invest Dermatol. 2008;128:2625–2630.
   PubMed Web of Science ®Google Scholar
• Asarch A, Barak O, Loo DS, et al. Th17 cells: a new paradigm for cutaneous inflammation. J Dermatol Treat. 2008;19:259–266.
   PubMed Web of Science ®Google Scholar
• Collamer AN, Guerrero KT, Henning JS, et al. Psoriatic skin lesions induced by tumor necrosis factor antagonist therapy: a literature review and potential mechanisms of action. Arthritis Rheum. 2008;59:996–1001.
   PubMed Web of Science ®Google Scholar
• Koo J. Population-based epidemiologic study of psoriasis with emphasis on quality of life assessment. Dermatol Clin. 1996;14:485–496.
   PubMed Web of Science ®Google Scholar
• Gelfand JM, Weinsten R, Porter SB, et al. Prevalence and treatment of psoriasis in the United Kingdom: a population-based study. Arch Dermatol. 2005;141: 1537–1541.
   PubMed Web of Science ®Google Scholar
• Yates VM, Watkinson G, Kelman A. Further evidence for an association between psoriasis, Crohn's disease and ulcerative colitis. Br J Dermatol. 1982;106:323–330.
   PubMed Web of Science ®Google Scholar
• Lee FI, Bellary SV, Francis C. Increased occurrence of psoriasis in patients with Crohn's disease and their relatives. Am J Gastroenterol. 1990;85:962–963.
   PubMed Web of Science ®Google Scholar
• Cohen AD, Dreiher J, Birkenfeld S. Psoriasis associated with ulcerative colitis and Crohn's disease. J Eur Acad Dermatol Venereol. 2009;23: 561–565.
   PubMed Web of Science ®Google Scholar
• Levine JS, Burakoff R. Extraintestinal, manifestations of inflammatory bowel disease. Gastroenterol Hepatol. 2011;7:235–241.
   PubMedGoogle Scholar
• Lolli E, Saraceno R, Calabrese E, et al. Psoriasis phenotype in inflammatory bowel disease: a case–control prospective study. J Crohns Colitis. 2015;9:699–707.
   PubMed Web of Science ®Google Scholar